Nothing Special   »   [go: up one dir, main page]

CO5580165A1 - Vacunas de rotavirus modificado - Google Patents

Vacunas de rotavirus modificado

Info

Publication number
CO5580165A1
CO5580165A1 CO00061886A CO00061886A CO5580165A1 CO 5580165 A1 CO5580165 A1 CO 5580165A1 CO 00061886 A CO00061886 A CO 00061886A CO 00061886 A CO00061886 A CO 00061886A CO 5580165 A1 CO5580165 A1 CO 5580165A1
Authority
CO
Colombia
Prior art keywords
nucleotide sequence
variant
rotavirus
seq
population
Prior art date
Application number
CO00061886A
Other languages
English (en)
Inventor
Colau Brigitte Desiree Alberte
Francoise Denamur
Isabelle Knott
Annick Poliszczak
Georges Thiry
Velde Vicent Valse
Original Assignee
Smithkline Beecham Bilogicals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9919468.0A external-priority patent/GB9919468D0/en
Priority claimed from GBGB9927336.9A external-priority patent/GB9927336D0/en
Application filed by Smithkline Beecham Bilogicals filed Critical Smithkline Beecham Bilogicals
Publication of CO5580165A1 publication Critical patent/CO5580165A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0216—Solid or semisolid forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12351—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Birds (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Una población de rotavirus atenuados, caracterizada porque comprende una sola variante o sustancialmente una sola variante, estando definida dicha variante por una secuencia de nucleótidos que codifica al menos una de las proteínas virales principales denominadas VP4 y VP7.Un rotavirus que comprende una secuencia de nucleótidos que codifica una proteína VP4, donde la secuencia de nucleótidos es como se muestra en la SEQ ID No. 1, y/o una secuencia de nucleótidos que codifica una proteína VP7 donde la secuencia de nucleótidos es como se muestra en la SEQ ID No. 2.1Un procedimiento para producir una población de rotavirus purificada que comprende una variante sustancialmente individual, comprendiendo el procedimiento:pasar una preparación de rotavirus sobre una línea celular adecuada, opcionalmente seleccionar un cultivo homogéneo usando las etapas de:dilución límite; oaislamiento de placas individuales; ycomprobar la presencia de una variante sustancialmente individual secuenciando una región apropiada de la secuencia del gen de VP4 y/o VP7.1 Una composición de vacuna que comprende un virus vivo atenuado de acuerdo con una cualquiera de las reivindicaciones 1 a 13, mezclado con un vehículo o adyuvante farmacéutico adecuado.
CO00061886A 1999-08-17 2000-08-17 Vacunas de rotavirus modificado CO5580165A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9919468.0A GB9919468D0 (en) 1999-08-17 1999-08-17 Vaccine
GBGB9927336.9A GB9927336D0 (en) 1999-11-18 1999-11-18 Vaccine

Publications (1)

Publication Number Publication Date
CO5580165A1 true CO5580165A1 (es) 2005-11-30

Family

ID=26315853

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00061886A CO5580165A1 (es) 1999-08-17 2000-08-17 Vacunas de rotavirus modificado

Country Status (42)

Country Link
US (4) US7285280B1 (es)
EP (1) EP1212084B1 (es)
JP (3) JP2003507040A (es)
KR (1) KR100695599B1 (es)
CN (1) CN100379451C (es)
AP (1) AP1768A (es)
AR (1) AR029643A1 (es)
AT (1) ATE327765T1 (es)
AU (1) AU767885B2 (es)
BG (1) BG65314B1 (es)
BR (1) BRPI0013357B8 (es)
CA (1) CA2379196C (es)
CO (1) CO5580165A1 (es)
CY (2) CY1106103T1 (es)
CZ (1) CZ302173B6 (es)
DE (2) DE122006000026I1 (es)
DK (1) DK1212084T3 (es)
DZ (1) DZ3219A1 (es)
EA (1) EA005952B1 (es)
ES (1) ES2260046T3 (es)
FR (1) FR06C0018I2 (es)
HK (1) HK1046860B (es)
HU (2) HU228975B1 (es)
IL (3) IL147926A0 (es)
LU (1) LU91251I2 (es)
MA (1) MA25489A1 (es)
MX (1) MXPA02001648A (es)
MY (1) MY133158A (es)
NL (1) NL300233I2 (es)
NO (2) NO328112B1 (es)
NZ (1) NZ517131A (es)
OA (1) OA12312A (es)
PE (1) PE20010487A1 (es)
PL (1) PL205550B1 (es)
PT (1) PT1212084E (es)
SI (1) SI1212084T1 (es)
SK (1) SK287261B6 (es)
TR (1) TR200200420T2 (es)
TW (1) TWI283270B (es)
UA (1) UA77388C2 (es)
UY (1) UY26297A1 (es)
WO (1) WO2001012797A2 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2260046T3 (es) * 1999-08-17 2006-11-01 Glaxosmithkline Biologicals S.A. Procedimiento para separar variantes rotavirus y vacuna de rotavirus vivos atenuados.
US6592869B2 (en) * 1999-08-24 2003-07-15 Teva Pharmaceutical Industries, Ltd. Vaccine composition and method of using the same
GB0020089D0 (en) * 2000-08-15 2000-10-04 Smithkline Beecham Biolog Vaccine Composition
KR20030026654A (ko) * 2001-09-26 2003-04-03 주식회사 씨트리 인간 로타바이러스의 활성을 저해하는 항체의 생산용 항원및 그의 제조방법과 이용
MXPA06002459A (es) 2003-09-02 2006-06-20 Glaxosmithkline Biolog Sa Vacuna.
GB0414787D0 (en) 2004-07-01 2004-08-04 Glaxosmithkline Biolog Sa Method
GB0503337D0 (en) 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
AU2006281566B2 (en) * 2005-08-17 2011-09-01 Glaxosmithkline Biologicals S.A. Rotavirus vaccine inducing heterotypic cross protection
CA2630220C (en) 2005-11-22 2020-10-13 Doris Coit Norovirus and sapovirus antigens
KR101051986B1 (ko) * 2006-09-28 2011-07-26 중앙대학교 산학협력단 인간로타바이러스 및 이를 이용한 백신 조성물
CA2668417A1 (en) * 2006-11-03 2008-05-15 Alphavax, Inc. Alphavirus and alphavirus replicon particle formulations and methods
EP2236617A1 (en) 2009-03-31 2010-10-06 Leukocare Ag Methods of terminal sterilization of biofunctional compositions
WO2010132561A2 (en) 2009-05-12 2010-11-18 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention New human rotavirus strains and vaccines
MY162326A (en) * 2009-07-13 2017-05-31 Bharat Biotech Int Ltd A composition useful as rotavirus vaccine and a method therefor
FR2960781B1 (fr) * 2010-06-07 2013-11-22 Sanofi Pasteur Preparation d'un vaccin oral sec stabilise, compose d'un virus vivant attenue
CN110227152A (zh) 2012-04-23 2019-09-13 巴拉特生物技术国际有限公司 轮状病毒疫苗组合物及其制备方法
NZ631348A (en) 2012-08-27 2017-02-24 Murdoch Childrens Res Inst Modified human rotaviruses and uses therefor
PL3299384T3 (pl) * 2015-05-21 2022-01-24 Xiamen University Skrócone białko vp4 rotawirusa i jego zastosowanie
CN108431214B (zh) 2015-10-05 2022-03-01 美国政府(由卫生和人类服务部的部长所代表) 人轮状病毒g9p[6]毒株和作为疫苗的用途
EP3373965A1 (en) * 2015-11-09 2018-09-19 CureVac AG Rotavirus vaccines
AU2016370401A1 (en) * 2015-12-18 2018-05-31 Merck Sharp & Dohme Corp. Thermally stable rotavirus vaccine formulations and methods of use thereof
MA44557B1 (fr) 2016-06-16 2021-11-30 Bharat Biotech Int Ltd Vaccin contre le rotavirus sans tampon, stable en milieu acide, et d'un faible volume de dose à administrer
GB201614799D0 (en) 2016-09-01 2016-10-19 Glaxosmithkline Biologicals Sa Compositions
CN110856493B (zh) * 2018-08-20 2022-02-25 中国烟草总公司黑龙江省公司牡丹江烟草科学研究所 一种植物病毒弱毒疫苗组合物、弱毒疫苗保存方法及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5927323B2 (ja) 1976-10-12 1984-07-05 花王株式会社 歯みがき組成物
US4341763A (en) * 1981-03-10 1982-07-27 Smithkline-Rit Methods of vaccinating humans against rotavirus infection
US4571385A (en) * 1983-06-27 1986-02-18 The United States Of America As Represented By The Department Of Health And Human Services Genetic reassortment of rotaviruses for production of vaccines and vaccine precursors
EP0152295B1 (en) 1984-02-09 1991-03-20 Royal Children's Hospital Research Foundation Live attenuated human rotavirus vaccine and preparation thereof
US5626851A (en) * 1987-11-30 1997-05-06 The Wistar Institute Of Anatomy And Biology Rotavirus reassortant vaccine
EP0557427B1 (en) 1990-11-16 1998-08-26 Children's Hospital Medical Center Human rotaviruses, vaccines and methods
US5471385A (en) * 1992-05-21 1995-11-28 Tsubakimoto Chain Co. Routeless guiding method for moving body
US5773009A (en) 1994-04-15 1998-06-30 The United States Of America As Represented By The Department Of Health And Human Services Rotavirus strain G9P11
AU3125795A (en) 1994-07-11 1996-02-09 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Attenuated human rotavirus vaccine
US5932223A (en) 1996-09-26 1999-08-03 Merck & Co., Inc. Rotavirus vaccine formulations
EP1891968A3 (en) * 1996-09-26 2008-09-03 Merck & Co., Inc. Rotavirus vaccine formulations
US6403098B1 (en) 1996-09-26 2002-06-11 Merck & Co., Inc. Rotavirus vaccine formulations
US6552024B1 (en) 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
ES2260046T3 (es) * 1999-08-17 2006-11-01 Glaxosmithkline Biologicals S.A. Procedimiento para separar variantes rotavirus y vacuna de rotavirus vivos atenuados.

Also Published As

Publication number Publication date
JP2003507040A (ja) 2003-02-25
DK1212084T3 (da) 2006-07-10
EP1212084B1 (en) 2006-05-31
UY26297A1 (es) 2001-03-16
DZ3219A1 (fr) 2001-02-22
MXPA02001648A (es) 2002-08-06
WO2001012797A3 (en) 2001-08-02
LU91251I9 (es) 2018-12-31
KR20020092344A (ko) 2002-12-11
HU228975B1 (en) 2013-07-29
CA2379196A1 (en) 2001-02-22
DE122006000026I1 (de) 2006-10-12
HUS1300072I1 (hu) 2019-11-28
NO328112B1 (no) 2009-12-07
JP2007319164A (ja) 2007-12-13
HK1046860B (zh) 2006-10-06
NO20020763L (no) 2002-04-16
PE20010487A1 (es) 2001-06-23
CZ302173B6 (cs) 2010-11-24
EA200200142A1 (ru) 2002-08-29
JP2011045374A (ja) 2011-03-10
CY2006004I1 (el) 2009-11-04
HUP0203335A3 (en) 2004-07-28
PT1212084E (pt) 2006-07-31
OA12312A (en) 2006-05-12
BR0013357A (pt) 2002-04-30
BG106417A (en) 2003-04-30
US20080057082A1 (en) 2008-03-06
AU6996100A (en) 2001-03-13
EP1212084A2 (en) 2002-06-12
IL147926A (en) 2008-03-20
ATE327765T1 (de) 2006-06-15
PL354135A1 (en) 2003-12-29
HK1046860A1 (en) 2003-01-30
BRPI0013357B8 (pt) 2021-05-25
NO2010011I2 (no) 2015-02-02
TR200200420T2 (tr) 2002-05-21
CN1379683A (zh) 2002-11-13
NZ517131A (en) 2003-07-25
ES2260046T3 (es) 2006-11-01
CN100379451C (zh) 2008-04-09
AP2002002424A0 (en) 2002-03-31
HUP0203335A1 (hu) 2003-02-28
IL188686A0 (en) 2008-04-13
AP1768A (en) 2007-08-16
CY2006004I2 (el) 2009-11-04
MY133158A (en) 2007-10-31
TWI283270B (en) 2007-07-01
US7790180B2 (en) 2010-09-07
SK2432002A3 (en) 2002-09-10
LU91251I2 (fr) 2006-08-14
BG65314B1 (bg) 2008-01-31
SK287261B6 (sk) 2010-04-07
DE60028390T2 (de) 2006-11-02
EA005952B1 (ru) 2005-08-25
CY1106103T1 (el) 2010-07-28
CZ2002522A3 (cs) 2002-05-15
FR06C0018I2 (fr) 2007-04-27
IL147926A0 (en) 2002-08-14
JP5474720B2 (ja) 2014-04-16
MA25489A1 (fr) 2002-07-01
DE60028390D1 (de) 2006-07-06
US7285280B1 (en) 2007-10-23
PL205550B1 (pl) 2010-04-30
AR029643A1 (es) 2003-07-10
WO2001012797A2 (en) 2001-02-22
KR100695599B1 (ko) 2007-03-14
US7790179B2 (en) 2010-09-07
UA77388C2 (uk) 2006-12-15
SI1212084T1 (sl) 2006-08-31
US20080063662A1 (en) 2008-03-13
NO2010011I1 (no) 2010-06-07
BRPI0013357B1 (pt) 2016-08-02
CA2379196C (en) 2015-05-26
NL300233I1 (nl) 2006-09-01
US20090130145A1 (en) 2009-05-21
AU767885B2 (en) 2003-11-27
NO20020763D0 (no) 2002-02-15
NL300233I2 (nl) 2006-10-02
FR06C0018I1 (es) 2006-07-21

Similar Documents

Publication Publication Date Title
CO5580165A1 (es) Vacunas de rotavirus modificado
ES2505695T3 (es) Composiciones inmunógenas para Streptococcus pyogenes
ES2563730T3 (es) Composiciones de proteína RSV F y procedimientos de fabricación de las mismas
Fernández-Fernández et al. Development of an antigen presentation system based on plum pox potyvirus
AR107020A2 (es) Vacuna de pcsk9 (proteína convertasa subtilisina-kexina tipo 9)
AR018603A1 (es) Un peptido, util para el tratamiento y/o profilaxis de la enfermedad de alzheimer y el sindrome de down, las composiciones farmaceuticas y vacunas que locontienen, el uso de dicho peptido para la preparacion de las composiciones farmaceuticas, una secuencia de aislado de adn, un plasmido o vector vi
EP4417695A2 (en) Modified circular rnas and methods of use thereof
BR9712852A (pt) Plasmìdeo, composição, processo de imunização de um indivìduo contra um patógeno, vacina recombinante, patógeno vivo atenuado, proteìna bl-1 substancialmente pura, vetor recombinante de expressão, e, anticorpo isolado
RU2008102654A (ru) Инактивированные химерные вакцины и связанные с ними способы применения
NO20073737L (no) Hjelp for influensavirus
AR047347A1 (es) Miembros de la familia cry9 de bacillus
BRPI0711608B1 (pt) Composição liofilizada, uso de antígeno viral, método de tratamento ou prevenção de vírus associado, método de adaptação de um vírus de uma linhagem celular adequada
RU2003103779A (ru) Экспрессионная система
US9457076B2 (en) Method for producing vaccinal viral strain of a virus of the Reoviridae family
UY24430A1 (es) Procedimiento para preparar vacuna contra tumores
AR053372A1 (es) Proteinas inmunologicas de lawsonia intracellularis
RU2018130683A (ru) Аттенуированный вирус инфекционного бронхита
ES2570665T3 (es) Factor de permisividad celular para virus, y usos del mismo
RU2003129068A (ru) Штаммы вируса репродуктивного и респираторного синдрома свиней (prrs) с ослабленной жизнеспособностью
AR019250A1 (es) Formas atenuadas del virus de la diarrea viral bovina, molecula de acido nucleico, vector, uso, metodo para modificar el genoma viral de tipo salvaje, genoma modificado, vacuna, metodo para atenuar un virus bvd de tipo salvaje
ES2902787T3 (es) Vacunas de ADNi y procedimientos para utilizar las mismas
WO2021171297A1 (en) Compositions comprising ltb and pathogenic antigens, and use thereof
AR036793A1 (es) Vacunas de acido nucleico que utilizan acidos nucleicos que codifican un antigeno de tumor con un acido nucleico que codifica una citoquina como adyuvante
CN1810823A (zh) 一种鸡特异性的CpG ODN及其应用
AR029168A1 (es) Una composicion acidos nucleicos peptidicos y un metodo para prepararla

Legal Events

Date Code Title Description
FG Application granted